Post-Menopausal Osteoporosis Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

DelveInsight's, "Postmenopausal Osteoporosis Pipeline Insight 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Post-Menopausal Osteoporosis Pipeline Insight Report
• DelveInsight's Post-Menopausal Osteoporosis pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Post-Menopausal Osteoporosis treatment.
• The leading Post-Menopausal Osteoporosis Companies includes Teva Pharmaceutical, Transcenta Holding, Shanghai Biomabs Pharmaceutical, HEXAL, Samsung Bioepis, Shenzhen Salubris Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd, Celltrion, Mabwell (Shanghai) Bioscience Co., Ltd., PhytoHealth, Luye Pharma, Sandoz International GmbH, Addpharma, and others.
• Promising Post-Menopausal Osteoporosis Pipeline Therapies includes TVB-009, SB16, ibandronate [Bonviva/Boniva], Risedronate, RGB-14-P, Romosozumab, Alendronate, and others.
• The Post-Menopausal Osteoporosis companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Osteoporosis R&D. The Post-Menopausal Osteoporosis pipeline therapies under development are focused on novel approaches to treat/improve Postmenopausal Osteoporosis.

Request a sample and discover the recent breakthroughs happening in the Post-Menopausal Osteoporosis Pipeline landscape @ Post-Menopausal Osteoporosis Pipeline Outlook Report- https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Post-Menopausal Osteoporosis Overview
Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population.

Post-Menopausal Osteoporosis Emerging Drugs Profile

• SB16: Samsung Bioepis
SB16 is a Denosumab biosimilar being developed by Samsung Bioepis to treat Postmenopausal osteoporosis. The company completed a Phase III clinical trial to compare the efficacy and safety of SB16 with the original drug on 457 post-menopausal osteoporosis patients.

• TST-002: Transcenta Holding
TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for severe osteoporosis. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone density and bone strength.
Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture. A Randomized, Double-Blind Phase II Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density is currently going on for it.

• SHR-1222: Jiangsu HengRui Medicine Co., Ltd.
Sclerostin is a glycoprotein inhibitor of osteoblast Wnt signaling produced by osteocytes. Research studies found that mutations of the sclerostin gene SOST are associated with high bone mass, which suggested that inhibitors of sclerostin might be used to increase bone mineral density and could therefore be developed as therapeutic intervention in patients with osteoporosis.
SHR-1222 is a novel SOST monoclonal antibody currently under phase I development in Post-menopausal osteoporosis.

For further information, refer to the detailed Post-Menopausal Osteoporosis Drugs Launch, Post-Menopausal Osteoporosis Developmental Activities, and Post-Menopausal Osteoporosis News, click here for Post-Menopausal Osteoporosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Post-Menopausal Osteoporosis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.

Post-Menopausal Osteoporosis Pipeline: Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Find out more about the Post-Menopausal Osteoporosis Pipeline Segmentation, Therapeutics Assessment, and Post-Menopausal Osteoporosis Emerging Drugs @ Post-Menopausal Osteoporosis Treatment Landscape- https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Post-Menopausal Osteoporosis Pipeline Report
• Coverage- Global
• Post-Menopausal Osteoporosis Companies- Teva Pharmaceutical, Transcenta Holding, Shanghai Biomabs Pharmaceutical, HEXAL, Samsung Bioepis, Shenzhen Salubris Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd, Celltrion, Mabwell (Shanghai) Bioscience Co., Ltd., PhytoHealth, Luye Pharma, Sandoz International GmbH, Addpharma, and others.
• Post-Menopausal Osteoporosis Pipeline Therapies- TVB-009, SB16, ibandronate [Bonviva/Boniva], Risedronate, RGB-14-P, Romosozumab, Alendronate, and others.
• Post-Menopausal Osteoporosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Post-Menopausal Osteoporosis Pipeline Companies and Therapies, click here @ Post-Menopausal Osteoporosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Postmenopausal osteoporosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Postmenopausal osteoporosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. TVB-009: Teva Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. TST-002: Transcenta Holding
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Postmenopausal osteoporosis Key Companies
21. Postmenopausal osteoporosis Key Products
22. Postmenopausal osteoporosis- Unmet Needs
23. Postmenopausal osteoporosis- Market Drivers and Barriers
24. Postmenopausal osteoporosis- Future Perspectives and Conclusion
25. Postmenopausal osteoporosis Analyst Views
26. Postmenopausal osteoporosis Key Companies
27. Appendix

Got Queries? Find out the related information on Post-Menopausal Osteoporosis Mergers and acquisitions, Post-Menopausal Osteoporosis Licensing Activities @ Post-Menopausal Osteoporosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/post-menopausal-osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Published Important Links-

https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
https://www.delveinsight.com/report-store/shigellosis-market
https://www.delveinsight.com/report-store/overactive-bladder-market
https://www.delveinsight.com/report-store/somatotropin-deficiency-market
https://www.delveinsight.com/report-store/herpes-zoster-market
https://www.delveinsight.com/report-store/visual-cycle-modulation-vcm-market
https://www.delveinsight.com/report-store/cataract-surgery-complications-market
https://www.delveinsight.com/report-store/vulvovaginal-candidiasis-market
https://www.delveinsight.com/report-store/erosive-hand-osteoarthritis-market
https://www.delveinsight.com/report-store/tissue-heart-valves-cardiovascular-prosthetic-devices-market
https://www.delveinsight.com/report-store/herpetic-keratitis-market-size
https://www.delveinsight.com/report-store/hot-flashes-in-prostate-cancer-market
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/thrombotic-thrombocytopenic-purpura-market
https://www.delveinsight.com/report-store/renal-tubular-acidosis-market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-market
https://www.delveinsight.com/report-store/hyperphosphatemia-market
https://www.delveinsight.com/report-store/hepatorenal-syndrome-market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market
https://www.delveinsight.com/report-store/von-hippel-lindau-disease-market
https://www.delveinsight.com/report-store/venous-thromboembolism-market
https://www.delveinsight.com/report-store/urea-cycle-disorders-market
https://www.delveinsight.com/report-store/tendonitis-market
https://www.delveinsight.com/report-store/tendinopathy-market
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
https://www.delveinsight.com/report-store/synovial-sarcoma-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/herpes-zoster-market
https://www.delveinsight.com/report-store/diabetic-nephropathy-market
https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
https://www.delveinsight.com/report-store/carbapenem-resistant-enterobacteriaceae-infection-market
https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
https://www.delveinsight.com/report-store/alpha-thalassemia-market
https://www.delveinsight.com/report-store/biliary-atresia-market
https://www.delveinsight.com/report-store/celiac-disease-cd-market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market
https://www.delveinsight.com/report-store/farbers-disease-market
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
https://www.delveinsight.com/report-store/radiotherapy-induced-oral-mucositis-market
https://www.delveinsight.com/report-store/radiation-dermatitis-market
https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market
https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
https://www.delveinsight.com/report-store/type-1-diabetes-market
https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market
https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-market
https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast
https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market
https://www.delveinsight.com/report-store/ocular-hypertension-market
https://www.delveinsight.com/report-store/heavy-metal-poisoning-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.